Chiesi Farmaceutici has patented a pharmaceutical formulation for intraduodenal administration containing melevodopa and carbidopa in a 1:5 ratio, with melevodopa completely dissolved and carbidopa as nanoparticles. The formulation aims to improve drug delivery efficiency. GlobalData’s report on Chiesi Farmaceutici gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Chiesi Farmaceutici SpA - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Chiesi Farmaceutici, Inhalation devices was a key innovation area identified from patents. Chiesi Farmaceutici's grant share as of January 2024 was 50%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11844860B2) discloses an aqueous pharmaceutical formulation designed for intraduodenal administration, containing carbidopa and melevodopa as active ingredients in a specific weight ratio of 1:5. The formulation ensures complete dissolution of melevodopa while carbidopa is present in the form of nanoparticles with a volume diameter ranging from 100 to 1000 nm. The formulation also includes various excipients, such as stabilization agents, wetting agents, and other additives to enhance the overall stability and efficacy of the formulation.

Furthermore, the patent claims detail the specific processes involved in preparing the carbidopa nanoparticles, including methods like suspension in acidic aqueous solutions, controlled precipitation against basic aqueous solutions, and coating the nanoparticles with excipients. The formulation is intended for the treatment of Parkinson's disease, with specific concentrations of melevodopa and carbidopa mentioned for optimal therapeutic effects. Additionally, a kit comprising the pharmaceutical formulation, a pharmaceutically acceptable aqueous vehicle, container means, and an infusion pump is also part of the patent claims, highlighting the comprehensive approach towards delivering the medication. Overall, the patent provides a detailed insight into the development of a specialized pharmaceutical formulation for effective treatment of Parkinson's disease through intraduodenal administration.

To know more about GlobalData’s detailed insights on Chiesi Farmaceutici, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies